{"id":"https://openalex.org/W65485959","doi":null,"title":"Physiopathologie et pharmacologie in vivo des recepteurs des benzodiazepines","display_name":"Physiopathologie et pharmacologie in vivo des recepteurs des benzodiazepines","alternate_titles":[],"publication_year":1994,"publication_date":"1994-01-01","ids":{"openalex":"https://openalex.org/W65485959","mag":"65485959"},"language":"fr","primary_location":{"id":"mag:65485959","doi":null,"is_oa":false,"landing_page_url":"https://www.theses.fr/1994PA112370","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"parent_works":[],"lineage":["https://openalex.org/W65485959"],"child_works_count":0,"type":"dissertation","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5016945907","display_name":"Michel Bottlaender","orcid":"https://orcid.org/0000-0002-2890-3653","observed_orcids":["https://orcid.org/0000-0002-2890-3653"]},"institutions":[],"countries":[],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Michel Bottlaender","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5016945907"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"reviewed_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.9907000064849854,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.9907000064849854,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11818","display_name":"Nicotinic Acetylcholine Receptors Study","score":0.0020000000949949026,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.0019000000320374966,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/benzodiazepine-receptor","display_name":"benzodiazepine receptor","score":0.9049999713897705},{"id":"https://openalex.org/keywords/gaba-a-receptor","display_name":"GABAA receptor","score":0.8600000143051147},{"id":"https://openalex.org/keywords/flumazenil","display_name":"flumazenil","score":0.6330000162124634},{"id":"https://openalex.org/keywords/positron-emission-tomography","display_name":"positron emission tomography","score":0.7870000004768372},{"id":"https://openalex.org/keywords/competitive-receptor-binding","display_name":"competitive receptor binding","score":0.5609999895095825},{"id":"https://openalex.org/keywords/anticonvulsant-activity","display_name":"anticonvulsant activity","score":0.9750000238418579},{"id":"https://openalex.org/keywords/nonhuman-primate-model","display_name":"nonhuman primate model","score":0.531000018119812},{"id":"https://openalex.org/keywords/selective-agonists","display_name":"selective agonists","score":0.46399998664855957},{"id":"https://openalex.org/keywords/anxiolytics","display_name":"anxiolytics","score":0.5889999866485596}],"concepts":[{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.5899138450622559},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.420783668756485},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.14122796058654785}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:65485959","doi":null,"is_oa":false,"landing_page_url":"https://www.theses.fr/1994PA112370","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8048999905586243}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W63368416","https://openalex.org/W13497296","https://openalex.org/W423053609","https://openalex.org/W7029831618","https://openalex.org/W358886491","https://openalex.org/W2051214011","https://openalex.org/W3014322994","https://openalex.org/W370795371","https://openalex.org/W1912649373","https://openalex.org/W3187889122"],"abstract_inverted_index":{"Les":[0],"benzodiazepines":[1,27],"sont":[2],"des":[3,26,37,68,84,109,134,166,177,193,200,203],"substances":[4,90],"anxiolytiques,":[5],"sedatives,":[6],"anticonvulsivantes":[7],"et":[8,111,150,169,179,190,206],"myorelaxantes":[9],"agissant":[10],"par":[11,49],"l'intermediaire":[12],"d'un":[13,195,214],"site":[14],"de":[15,51,89,114,136,153,211,216],"liaison":[16,61],"specifique":[17,67],"faisant":[18],"partie":[19],"du":[20,35,41,63,103,118,209],"complexe":[21,119],"recepteur":[22,25,120,217],"gaba#a:":[23],"le":[24,44,75,148,151,175,183],"(rbz).":[28],"Nous":[29],"avons":[30,79,129],"etudie":[31,101],"differents":[32],"aspects":[33],"moleculaires":[34],"fonctionnement":[36,176],"rbz":[38,93,110,201],"au":[39],"sein":[40],"cerveau":[42],"chez":[43,74],"sujet":[45],"vivant.":[46],"La":[47],"tomographie":[48],"emission":[50],"positons":[52],"a":[53,162],"ete":[54],"utilisee":[55],"pour":[56,147],"suivre,":[57],"in":[58,132,172],"vivo,":[59,133],"la":[60,115,164,191],"cerebrale":[62],"#1#1cflumazenil":[64],"(un":[65],"radioligand":[66],"rbz),":[69],"dans":[70,122,174,202],"differentes":[71],"conditions":[72],"experimentales:":[73],"primate":[76],"infra-humain,":[77],"nous":[78,128],"quantifie":[80],"les":[81,92,106,188,198],"parametres":[82],"pharmacologiques":[83,108],"rbz,":[85,178],"caracterise":[86],"l'interaction":[87],"competitive":[88],"avec":[91],"ainsi":[94],"que":[95],"l'activite":[96],"anticonvulsivante":[97],"qui":[98,143],"en":[99],"resulte,":[100],"l'influence":[102],"gaba":[104],"sur":[105,182],"proprietes":[107],"montre":[112,130],"l'importance":[113],"composition":[116],"moleculaire":[117],"gaba#a":[121],"son":[123],"role":[124],"physiologique.":[125],"Chez":[126],"l'homme,":[127],"que,":[131],"zones":[135],"perte":[137],"neuronale":[138],"peuvent":[139],"etre":[140],"detectees,":[141],"ce":[142],"est":[144],"tres":[145],"important":[146],"diagnostic":[149],"suivi":[152],"certaines":[154],"atteintes":[155],"neurologiques.":[156],"Ces":[157],"resultats,":[158],"d'une":[159],"part,":[160,181],"contribuent":[161],"accroitre":[163],"connaissance":[165],"mecanismes":[167],"physiologiques":[168],"physiopathologiques":[170],"impliques":[171],"vivo":[173],"d'autre":[180],"plan":[184],"therapeutique":[185],"permettent":[186],"d'optimiser":[187],"doses":[189],"chronologie":[192],"prises":[194],"medicament,":[196],"d'etudier":[197],"modifications":[199],"situations":[204],"pathologiques,":[205],"montrer":[207],"l'interet":[208],"developpement":[210],"medicaments":[212],"selectifs":[213],"sous-type":[215]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W65485959","counts_by_year":[],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
